Name: NSMCE2 (Nucleotide-Sensitive Motif-Containing Extrase 2)

Target Name: NSMCE2

NCBI ID: G286053

NSMCE2

Name: NSMCE2 (Nucleotide-Sensitive Motif-Containing Extrase 2)

Synonyms: NSMCE2 gene, NSMCE2 protein, NSMCE2 antigen

Description:

Nucleotide-Sensitive Motif-Containing Extrase 2 (NSMCE2) is a non-coding RNA molecule located in the human genome at position 6,112.2 on chromosome 16. NSMCE2 is a small non-coding RNA molecule that contains a unique motif that is composed of a -sensitive motif and a conserved stem-loop structure. This motif is responsible for the protein's ability to interact with DNA and other RNA molecules.

NSMCE2 has been identified as a potential drug target and a biomarker for various diseases, including cancer, neurodegenerative diseases, and immune-related disorders. Its unique structure and function make it an attractive target for researchers to study and develop new therapeutic approaches.

Structure and Function:

The structure of NSMCE2 is unique among non-coding RNAs. It consists of a stem-loop structure that is composed of a series of alternating G/C and A/T base pairs. The stem-loop is flanked by a variable number of degenerate extensions, which are composed of a combination of G/C and A/T base pairs. The G/C base pairs in the stem-loop are modified by a specific motif, which consists of a nucleotide-sensitive base (A) and a base that is susceptible to base mispairing, such as G or C.

The unique motif of NSMCE2 allows it to interact with DNA and other RNA molecules. The stem-loop's variable extensions contain base pairs that are susceptible to base mispairing, which allows the molecule to form a stable double helix with DNA or other RNA molecules. This interaction between the molecule and the target RNA or DNA can lead to the formation of NSMCE2-protein-DNA or NSMCE2-RNA-NSMCE2 hybrids, which can be used for various biochemical and biomedical studies.

NSMCE2 has been shown to play a role in various diseases, including cancer, neurodegenerative diseases, and immune-related disorders. For example, studies have shown that high levels of NSMCE2 are associated with poor prognosis in cancer patients and that the expression of NSMCE2 is increased in neurodegenerative diseases. Additionally, research has suggested that NSMCE2 may play a role in modulating the immune response and increasing the risk of certain autoimmune disorders.

Drug Targeting:

NSMCE2 has been identified as a potential drug target due to its unique structure and function. The nucleotide-sensitive motif and the stem-loop structure make it an attractive target for small molecule inhibitors. Researchers have synthesized various small molecules that bind to the NSMCE2 motif and have shown that these inhibitors can reduce the levels of NSMCE2 in various cell types.

One of the most promising small molecules that have been shown to interact with NSMCE2 is the drugletrepanide, which is a peptide that contains a nucleotide-sensitive base (A) and a base that is susceptible to base mispairing (G). Studies have shown that the drugletrepanide can reduce the levels of NSMCE2 in various cell types, including cancer cells, and that it has anti-tumor effects.

Another small molecule that has been shown to interact with NSMCE2 is the RNA interference drug, RNA-interference (RNAi) inhibitor, GFP-PEG, which consists of a GFP tag and a small molecule inhibitor that targets the NSMCE2 stem

Protein Name: NSE2 (MMS21) Homolog, SMC5-SMC6 Complex SUMO Ligase

Functions: E3 SUMO-protein ligase component of the SMC5-SMC6 complex, a complex involved in DNA double-strand break repair by homologous recombination (PubMed:16055714, PubMed:16810316). Is not be required for the stability of the complex (PubMed:16055714, PubMed:16810316). The complex may promote sister chromatid homologous recombination by recruiting the SMC1-SMC3 cohesin complex to double-strand breaks (PubMed:16055714, PubMed:16810316). The complex is required for telomere maintenance via recombination in ALT (alternative lengthening of telomeres) cell lines and mediates sumoylation of shelterin complex (telosome) components which is proposed to lead to shelterin complex disassembly in ALT-associated PML bodies (APBs) (PubMed:17589526). Acts as an E3 ligase mediating SUMO attachment to various proteins such as SMC6L1 and TSNAX, the shelterin complex subunits TERF1, TERF2, TINF2 and TERF2IP, RAD51AP1, and maybe the cohesin components RAD21 and STAG2 (PubMed:16055714, PubMed:16810316, PubMed:17589526, PubMed:31400850). Required for recruitment of telomeres to PML nuclear bodies (PubMed:17589526). SUMO protein-ligase activity is required for the prevention of DNA damage-induced apoptosis by facilitating DNA repair, and for formation of APBs in ALT cell lines (PubMed:17589526). Required for sister chromatid cohesion during prometaphase and mitotic progression (PubMed:19502785)

The "NSMCE2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NSMCE2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets